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Background: Higher body-mass index (BMI) and waist-to-hip ratio (WHR) increase the risk of 64 
cardiovascular disease, but the extent to which this is mediated by blood pressure, diabetes, lipid 65 
traits and smoking is not fully understood.  66 
Methods: Using consortia and UK Biobank genetic association summary data from 140,595 to 67 
898,130 participants predominantly of European ancestry, Mendelian randomization mediation 68 
analysis was performed to investigate the degree to which systolic blood pressure (SBP), diabetes, 69 
lipid traits and smoking mediated an effect of BMI and WHR on risk of coronary artery disease (CAD), 70 
peripheral artery disease (PAD) and stroke. 71 
Results: The odds ratio of CAD per 1-standard deviation increase in genetically predicted BMI was 72 
1.49 (95% CI 1.39 to 1.60). This attenuated to 1.34 (95% CI 1.24 to 1.45) after adjusting for 73 
genetically predicted SBP (proportion mediated 27%, 95% CI 3% to 50%), to 1.27 (95% CI 1.17 to 74 
1.37) after adjusting for genetically predicted diabetes (41% mediated, 95% CI 18% to 63%), to 1.47 75 
(95% CI 1.36 to 1.59) after adjusting for genetically predicted lipids (3% mediated, 95% -23% to 29%), 76 
and to 1.46 (95% CI 1.34 to 1.58) after adjusting for genetically predicted smoking (6% mediated, 77 
95% CI -20% to 32%). Adjusting for all the mediators together, the estimate attenuated to 1.14 (95% 78 
CI 1.04 to 1.26; 66% mediated, 95% CI 42% to 91%). A similar pattern was observed when 79 
considering genetically predicted WHR as the exposure, and PAD or stroke as the outcome. 80 
Conclusions: Measures to reduce obesity will lower risk of cardiovascular disease primarily by 81 
impacting on downstream metabolic risk factors, particularly diabetes and hypertension. Reduction 82 
of obesity prevalence alongside control and management of its mediators is likely to be most 83 




Cardiovascular disease (CVD) is the leading cause of death and disability worldwide(1). Obesity can 86 
contribute towards CVD risk through effects on hyperglycaemia, hypertension, dyslipidaemia, and 87 
smoking behaviour(2-5). The global prevalence of obesity has more than tripled in the last 40 years, 88 
with an even greater rise in incidence amongst children(6). It is estimated that by 2030, 89 
approximately half of the US population will be obese(7). While obesity prevention remains the 90 
priority, there are also treatments available to effectively manage the downstream mediators 91 
through which obesity causes CVD(8-11). Understanding of such pathways is therefore paramount to 92 
reducing cardiovascular risk. 93 
Obesity can be measured by various means. It is defined by the World Health Organisation as a 94 
body-mass index (BMI) of greater than or equal to 30kg/m2 (12), although this cut-off threshold can 95 
vary between different populations. However, BMI is a not a direct measure of adiposity, and is also 96 
correlated with fat-free mass(12). Assessment of obesity using waist-to-hip ratio (WHR) is less 97 
subject to influence from height and muscle mass, and is positively associated with cardiovascular 98 
risk in individuals with a normal BMI(13, 14). Thus, BMI and WHR represent distinct measures of 99 
body fat that may differentially affect risk of CVD outcomes. Conventional observational studies 100 
have shown that the relationship between obesity measures such as BMI and WHR with CVD is 101 
attenuated when adjustment is made for cardiometabolic risk factors such as blood pressure, lipid 102 
traits or measures of glycaemia(15). This has allowed for estimation of the proportion of the effect 103 
of obesity that is mediated through these intermediates(15). However, such observational analysis is 104 
vulnerable to bias from environmental confounding factors and measurement error, both of which 105 
can result in underestimation of the proportion of effect mediated(16, 17). The Mendelian 106 
randomization (MR) approach uses genetic variants as instruments for studying the effect of 107 
modifying an exposure on an outcome, and has now been extended to perform mediation 108 
analyses(16, 18). Such use of genetic variants whose allocation is not affected by environmental 109 
confounding factors means that MR estimates are less vulnerable to confounding from 110 
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environmental factors. Furthermore, use of genetic variants that are associated with the exposure 111 
(BMI or WHR) in large populations including individuals of different ages means that their 112 
association estimates are typically less vulnerable to measurement error or variation related to the 113 
timing of measurement(16).  114 
The increasing availability of large-scale genome-wide association study (GWAS) data has greatly 115 
facilitated MR analyses considering cardiovascular risk factors and outcomes. In this study, we aimed 116 
to use such data within the MR framework to investigate the role of blood pressure, diabetes, 117 
fasting glucose, lipid traits and smoking in mediating the effect of BMI and WHR on coronary artery 118 
disease (CAD), peripheral arterial disease (PAD) and stroke risk.  119 
 120 
Methods 121 
Ethical approval, data availability, code availability and reporting 122 
The data used in this work are publicly available and the studies from which they were obtained are 123 
cited. All these studies obtained relevant participant consent and ethical approval. The results from 124 
the analyses performed in this work are presented in the main manuscript or its supplementary files. 125 
All code used for this work are available upon reasonable request to the corresponding author. This 126 
paper has been reported based on recommendations by the STROBE-MR Guidelines (Research 127 
Checklist)(19). The study protocol and details were not pre-registered.  128 
Data sources 129 
Genetic association estimates for BMI and WHR were obtained from the GIANT Consortium GWAS 130 
meta-analysis of 806 834 and 697 734 European-ancestry individuals respectively(20). Genetic 131 
association estimates for SBP were obtained from a GWAS of 318 417 White British individuals in the 132 
UK Biobank, with correction made for any self-reported anti-hypertensive medication use by adding 133 
10mmHg to the mean SBP measured from two automated recordings that were taken two minutes 134 
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apart at baseline assessment(21). Previous methodological work has supported that the addition of 135 
a constant value to the observed blood pressure in individuals taking antihypertensive medication as 136 
a strategy that optimises statistical power while minimising bias(22). Genetic association estimates 137 
for lifetime smoking (referred to hereon as smoking) were obtained from a GWAS of 462 690 138 
European-ancestry individuals in the UK Biobank(23). A lifetime measure of smoking was created 139 
based on self-reported age at initiation, age at cessation and cigarettes smoked per day(23). Genetic 140 
association estimates for liability to diabetes came from the DIAGRAM Consortium GWAS meta-141 
analysis of 74 124 cases and 824 006 controls, all of European ancestry(24). Genetic association 142 
estimates for plasma fasting glucose were obtained by using PLINK software to carry out a meta-143 
analysis of MAGIC Consortium GWAS summary data from separate analyses of 67 506 men and 73 144 
089 women who were not diabetic(25, 26). Genetic association estimates for fasting serum low-145 
density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and triglycerides 146 
were obtained from the Global Lipids Genetic Consortium GWAS of 188,577 European-ancestry 147 
individuals(27). Genetic association estimates for CAD were obtained from the 148 
CARDIoGRAMplusC4D Consortium 1000G multi-ethnic GWAS (77% European-ancestry) of 60 801 149 
cases and 123 504 controls(28). Genetic association estimates for PAD were obtained from the 150 
Million Veterans Program multi-ethnic (72% European-ancestry) GWAS of 31 307 cases and 211 753 151 
controls(29). Genetic association estimates for stroke were obtained from the MEGASTROKE multi-152 
ethnic (86% European-ancestry) GWAS of 67 162 cases (of any stroke) and 454 450 controls(30). 153 
Population characteristics and specific trait definitions relating to all these summary genetic 154 
association estimates are available in their original publications. For the analyses performed in this 155 
current work, genetic variants from different studies were aligned by their effect alleles and no 156 
exclusions were made for palindromic variants. Only variants for which genetic association estimates 157 
were available for all the traits being investigated in any given analysis were considered. In order to 158 
maintain consistency in the variants employed as instruments across different analyses, proxies 159 
were not used. 160 
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Instrument selection 161 
To estimate the total effect of BMI and WHR respectively on the considered cardiovascular 162 
outcomes, instruments were selected as single-nucleotide polymorphisms (SNPs) that associated 163 
with BMI or WHR at genome-wide significance (P<5x10-8) and were in pair-wise linkage 164 
disequilibrium (LD) r2<0.001. The percentage variance in BMI and WHR explained by the variants 165 
selected as their respective instruments was estimated as previously described(31). To select 166 
instruments for mediation analysis, all SNPs related to the considered exposure (BMI or WHR) or 167 
mediators at genome-wide significance were pooled and clumped to pairwise LD r2<0.001 based on 168 
the lowest P-value for association with any trait. All clumping was performed using the 169 
TwoSampleMR package in R(32).  170 
Total effects 171 
Random-effects inverse-variance weighted (IVW) MR was used as the main analysis for estimating 172 
the total effects of genetically predicted BMI and genetically predicted WHR respectively on each of 173 
the considered CVD outcomes(33). The contamination-mixture method, weighted median and MR-174 
Egger were used in sensitivity analyses to explore the robustness of the findings to potential 175 
pleiotropic effects of the variants(34-36). The contamination-mixture model makes the assumption 176 
that MR estimates from valid instruments follow a normal distribution that centres on the true 177 
causal effect estimate, while those calculated from invalid instrument variants follow a normal 178 
distribution centred on the null(35). This allows for a likelihood function to be specified and 179 
maximized when allocating each variant to one of the two mixture distributions(35). The weighted 180 
median approach orders the MR estimates from individual variants by their magnitude weighted for 181 
their precision and selects the median as the overall MR estimate, calculating standard error by 182 
bootstrapping(34). MR-Egger regresses the variant-outcome association estimates against the 183 
variant-exposure association estimates, weighted for the precision of the variant-outcome 184 
estimates(36). It gives a valid MR estimate and test for the presence of directional pleiotropy in 185 
scenarios where any direct effect of the variants on the outcome is not correlated to their 186 
9 
 
association with the exposure(36). The MendelianRandomization package (version 0.4.2) in R 187 
(version 3.6.3) was used for performing the IVW, contamination-mixture, weighted median MR and 188 
MR-Egger analyses(37). 189 
Mediation analysis 190 
To estimate the direct effect of genetically predicted BMI and genetically predicted WHR on each of 191 
the three considered CVD outcomes that was not being mediated by the investigated intermediary 192 
risk factors, summary data multivariable MR was performed(38-40). Specifically, the orientations of 193 
all genetic association estimates were harmonized and the variant-outcome genetic association 194 
estimates were regressed on the variant-exposure and variant-mediator estimates, weighted for the 195 
precision of the variant-outcome association, with the intercept fixed to zero(40). Using this 196 
approach, adjustment was made for genetically predicted SBP, diabetes, smoking and lipid traits 197 
(LDL-C, HDL-C and triglycerides together) in turn, and finally including all mediators together in a 198 
joint model. In a sensitivity analysis, genetically predicted diabetes was excluded from this joint 199 
model to remove any bias that might be introduced because of its binary nature(41). For analyses 200 
considering genetically predicted fasting glucose in non-diabetics instead of genetically predicted 201 
diabetes, the corresponding genetic association data were substituted. Diabetes and fasting glucose 202 
were not included together in the same model. 203 
Multivariable MR mediation analysis was performed to estimate the proportion of the effect of BMI 204 
and WHR respectively on CAD, PAD and stroke that was mediated through each of  the considered 205 
risk factors, and also all of them together(16). Specifically, the direct effect of genetically predicted 206 
BMI and genetically predicted WHR respectively was divided by their total effect and subtracted 207 
from 1, with standard errors estimated using the propagation of error method(16, 18). 208 
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Independent effects of genetically predicted BMI and WHR  209 
The direct effects of genetically predicted BMI and genetically predicted WHR on the considered 210 
CVD outcomes that are not mediated through each other were measured by including only these 211 
two traits together as exposures in the summary data multivariable MR model described above. 212 
 213 
Results 214 
Total effects 215 
The variants selected as instruments for BMI and WHR explain 5.7% and 3.6% of their variance 216 
respectively. Considering total effects, there was consistent evidence across the IVW, 217 
contamination-mixture, weighted median and MR-Egger methods that both higher genetically 218 
predicted BMI and higher genetically predicted WHR increased CAD, PAD and stroke risk 219 
(Supplementary Figure 1). The confidence intervals of the MR-Egger estimates were wider than for 220 
the other methods, consistent with its lower statistical power(42). The MR-Egger intercept did not 221 
provide evidence to suggest directional pleiotropy in any analysis (P>0.05 in all analyses). In the main 222 
IVW MR analysis, the odds ratio per 1-standard deviation (SD) increase in genetically predicted BMI 223 
(4.81kg/m2) for CAD risk was 1.49 (95% confidence interval [CI] 1.39 to 1.60), for PAD risk was 1.70 224 
(95% CI 1.58 to 1.82), and for stroke risk was 1.22 (95% CI 1.15 to 1.29). For a 1-SD increase in 225 
genetically predicted WHR (0.09), this was 1.54 (95% CI 1.38 to 1.71) for CAD risk, 1.55 (95% CI 1.40 226 
to 1.71) for PAD risk, and 1.30 (95% CI 1.21 to 1.40) for stroke risk. 227 
Mediation analysis 228 
There was attenuation in the associations of genetically predicted BMI and genetically predicted 229 
WHR with the three CVD outcomes after adjusting for genetically predicted SBP, diabetes, lipid traits 230 
(LDL-C, HDL-C and triglycerides together) and smoking, either separately or in the same joint model 231 
(Figure 1). The 49% (95% CI 39% to 60%) increased risk of CAD conferred per 1-SD increase in 232 
genetically predicted BMI attenuated to 34% (95% CI 24% to 45%) after adjusting for genetically 233 
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predicted SBP, to 27% (95% CI 17% to 37%) after adjusting for genetically predicted diabetes, to 47% 234 
(95% CI 36% to 59%) after adjusting for genetically predicted lipids, and to 46% (95% CI 34% to 58%) 235 
after adjusting for genetically predicted smoking. Adjusting for all the mediators together in the 236 
same model, the association attenuated to 14% (95% CI 4% to 26%).  237 
The percentage attenuation in the total effects of genetically predicted BMI and WHR respectively 238 
on the three CVD outcomes after adjusting for the mediators is depicted in Figure 2. For the effect of 239 
genetically predicted BMI on CAD risk, 27% (95% CI 3% to 50%) was mediated by genetically 240 
predicted SBP, 41% (95% 18% to 63%) was mediated by genetically predicted diabetes, 3% (-23% to 241 
29%) was mediated by  genetically predicted lipids, and 6% (95% CI -20% to 32%) was mediated by 242 
genetically predicted smoking. All the mediators together accounted for 66% (95% CI 42% to 91%) of 243 
the total effect of genetically predicted BMI on CAD risk.  244 
A joint model including all considered mediators except genetically predicted diabetes was also 245 
constructed (Supplementary Figure 2). Adjusting together for all the mediators except genetically 246 
predicted diabetes, the association of genetically predicted BMI with CAD risk attenuated from odds 247 
ratio 1.49 (95% CI 1.39 to 1.60) to 1.27 (95% CI 1.16 to 1.40).  248 
There was little change in the association of either genetically predicted BMI or genetically predicted 249 
WHR with risk of the three CVD outcomes after adjusting for genetically predicted fasting glucose in 250 
non-diabetic individuals (Figure 3). 251 
Independent effects of genetically predicted BMI and WHR  252 
Both genetically predicted BMI and genetically predicted WHR had direct effects on CAD, PAD and 253 
stroke after mutual adjustment (Figure 4). The increased CAD risk attributed to a 1-SD higher 254 
genetically predicted BMI attenuated from 49% (95% CI 39% to 60%) to 32% (95% CI 20% to 45%) 255 
after adjusting for genetically predicted WHR, and the increased CAD risk attributed to a 1-SD higher 256 
genetically predicted WHR attenuated from 54% (95% CI 38% to 71%) to 33% (95% CI 18% to 50%) 257 





This study uses large-scale genetic association data within the MR paradigm to investigate the role of 261 
SBP, diabetes, lipid traits and smoking in mediating the effect of BMI and WHR on CAD, PAD and 262 
stroke risk. The results support that the majority of the effects of obesity on CVD are mediated 263 
through these risk factors, with diabetes and blood pressure being the most notable and accounting 264 
for approximately one-third and one-quarter of the effect respectively. In contrast, the analysis of 265 
genetically predicted fasting glucose in non-diabetic individuals did not provide any evidence to 266 
support its role in mediating the effect of obesity on CVD risk. Previous work has supported an effect 267 
of diabetes liability, fasting glucose and glycated haemoglobin on CVD risk(43, 44). Taken together 268 
with our current findings, this suggests that obesity may be affecting CVD risk by increasing diabetes 269 
liability and non-fasting (postprandial) glucose levels. Similarly, while lipid traits are known to affect 270 
CVD risk(45), our current study suggests that obesity is conferring only a small proportion of its 271 
effect on CVD risk through this pathway. Consistent with this, previous work has supported an effect 272 
of BMI on HDL-C and triglyceride levels, but not LDL-C(44). 273 
In our analyses, the sum of the estimated mediating effects of the various risk factors considered 274 
individually was comparable to their total mediating effect estimated when considering them all 275 
together in the same model, consistent with them acting through distinct mechanisms. Including 276 
genetically predicted BMI and genetically predicted WHR in the same model produced evidence 277 
consistent with these traits having direct effects on CVD risk independently of each other. It follows 278 
that rather than analysing BMI or WHR alone, they should be considered together as they capture 279 
different aspects of adiposity. 280 
Our findings have important clinical and public health implications. Behavioural interventions to 281 
reduce obesity can have inadequate long term effects(46), pharmacological treatments may be 282 
limited by unfavourable adverse effect profiles(47), and surgical procedures are often reserved for 283 
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only severe cases(48). While preventing obesity remains the priority, this work supports that the 284 
majority of its cardiovascular consequences may also be managed by effectively controlling its 285 
downstream mediators, most notably diabetes and raised blood pressure, for which effective 286 
pharmacological interventions are available. This has relevance for the more than 640 million 287 
individuals worldwide currently living with obesity(49), and the many more forecasted to become 288 
obese in coming years(50). Such holistic consideration of obesity together with its mediators could 289 
contribute to a shift from the single-disease focus of health systems towards prioritizing multi-290 
morbidity and promoting individual and societal wellness(51).  291 
Our analyses were also suggestive of some possible residual effect of BMI on CVD risk even after 292 
adjusting for all the considered mediating risk factors, consistent with metabolically healthy obesity 293 
still conferring increased CVD risk(52). In contrast, the investigation of WHR was consistent with an 294 
absence of any direct effect on CVD risk after accounting for the all mediating risk factors together, 295 
suggesting that WHR may be entirely influencing CVD through downstream metabolic traits. Taken 296 
together, these results suggest that unless the growing obesity epidemic is effectively tackled, we 297 
risk undoing the large reductions in CVD mortality achieved over past decades(1). Population-based 298 
approaches that decrease obesity by addressing key upstream drivers such as poor diet and physical 299 
inactivity have substantial potential for impact and are also effective for reducing health 300 
inequalities(53, 54). 301 
The results of our current study can be contrasted to those from a large-scale observational analysis 302 
of 1.8 million people across 97 studies(15, 55). This previous work estimated that 46% (95% CI 42% 303 
to 50%) of the excess risk conferred by raised BMI on CAD and 76% (95% CI 65% to 91%) on stroke 304 
were mediated by effects on blood pressure, glucose levels and lipid traits, with blood pressure 305 
being the most important and mediation for stroke being greatest(15). However, the approach and 306 
data used in our current study offers a number of possible improvements. Our work includes a 307 
greater repertoire of risk factors and CVD outcomes than have been considered together 308 
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previously(15, 44), in particular drawing on recently available GWAS summary data to study smoking 309 
and PAD(23, 29). MR analysis uses randomly allocated genetic variants that represent lifelong 310 
cumulative liability to the traits for which they serve as instruments and can therefore help 311 
overcome the environmental confounding that may bias conventional observational studies(16). 312 
Consistent with this, our MR results indicate that these risk factors mediate a greater proportion of 313 
the effect of obesity than suggested by previous conventional observational analyses(15). 314 
Furthermore, our MR estimates are comparable to those obtained in previous MR studies 315 
considering BMI and WHR as exposures and different types of CVD as the outcome(44, 56, 57). 316 
Also of relevance here, we considered genetic liability to diabetes and genetically predicted fasting 317 
glucose in non-diabetic individuals as separate risk factors. Our findings support the concept that 318 
obesity traits confer an increased risk of CVD specifically through liability to diabetes, rather than 319 
variation in fasting glucose levels within the normal physiological range. This is important because 320 
fasting glucose may have a non-linear association with CVD risk(58), only having detrimental effects 321 
beyond a certain point(59).  322 
Our current study also has limitations. The aim of the current work was to investigate the degree to 323 
which cardiometabolic traits mediate the effects of BMI and WHR on CVD outcomes, and our study 324 
did not extend to investigate any possible role of BMI or WHR in mediating the effects of the 325 
considered cardiometabolic traits on CVD risk. The genetic association data used in this work are 326 
drawn from predominantly European populations, and should therefore be interpreted with caution 327 
when extrapolating to other ethnic groups. Diabetes is a binary outcome, and as such our 328 
consideration of genetically predicted diabetes could introduce bias into the mediation analysis 329 
because not all individuals possessing such genetic liability develop diabetes-related traits(41). SBP 330 
was used as a proxy for studying the effects of blood pressure more generally. Given the high degree 331 
of phenotypic and genetic correlation between blood pressure traits(60), this would seem unlikely to 332 
affect the conclusions drawn. A theoretical weakness of the MR approach relates to bias from 333 
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pleiotropic effects of the genetic variants incorporated as instruments for the traits under study, 334 
whereby they may directly affect the outcome through pathways independent of the exposure or 335 
mediators being considered. Although such bias cannot be entirely excluded, it is reassuring that we 336 
obtained similar MR estimates for the total effect of BMI and WHR respectively on the three CVD 337 
outcomes when performing the IVW, contamination-mixture, weighted median and MR-Egger 338 
methods that each make different assumptions concerning the presence of pleiotropic variants(42). 339 
Finally, there is currently no available method for assessing instrument strength within the two-340 
sample multivariable MR setting, and we could therefore not assess potential vulnerability to weak 341 
instrument bias(38).  342 
In conclusion, this work using the MR framework suggests that the majority of the effects of obesity 343 
on CVD risk are mediated through metabolic risk factors, most notably diabetes and blood pressure. 344 
Comprehensive public health measures that target the reduction of obesity prevalence alongside 345 
control and management of its downstream mediators are likely to be most effective for minimizing 346 
the burden of obesity on individuals and health systems alike.   347 
 348 
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Figure legends 553 
Figure 1. Direct effects of genetically predicted body mass index (BMI) and genetically predicted 554 
waist-to-hip ratio (WHR) on coronary artery disease (CAD), peripheral artery disease (PAD) and 555 
stroke, estimated after adjusting for genetic liability to mediators separately and together in the 556 
same model. The y-axis details the genetically predicted mediator(s) for which adjusted was made. 557 
Blood pressure refers to systolic blood pressure. Lipids refers to serum low-density lipoprotein 558 
cholesterol, high-density lipoprotein cholesterol and triglycerides considered together in one model. 559 
CI: confidence interval; OR: odds ratio; SD: standard deviation. 560 
Figure 2. Proportion (as a percentage) of the respective effects of genetically predicted body mass 561 
index (BMI) and genetically predicted waist-to-hip ratio (WHR) on coronary artery disease (CAD), 562 
peripheral artery disease (PAD) and stroke that are mediated through the genetically predicted 563 
risk factors individually and together. The y-axis details the genetically predicted mediator(s) for 564 
which adjustment was made. Blood pressure refers to systolic blood pressure. Lipids refers to serum 565 
low-density lipoprotein cholesterol, high-density lipoprotein cholesterol and triglycerides considered 566 
together in one model. CI: confidence interval. 567 
Figure 3. Direct effects of body mass index (BMI) and waist-to-hip ratio (WHR) on coronary artery 568 
disease (CAD), peripheral artery disease (PAD) and stroke, estimated after no adjustment and 569 
after adjustment for genetically predicted fasting glucose in non-diabetics. CI: confidence interval; 570 
OR: odds ratio; SD: standard deviation. 571 
Figure 4. Direct effects of genetically predicted body mass index (BMI) and genetically predicted 572 
waist-to-hip ratio (WHR) on coronary artery disease (CAD), peripheral artery disease (PAD) and 573 
stroke, estimated after adjusting for each other. CI: confidence interval; OR: odds ratio; SD: 574 
standard deviation.  575 




